Diagnostic Accuracy of On-line Quantitative Flow Ratio (QFR). FAVOR II Europe-Japan (FAVOR II EJ)

December 27, 2019 updated by: Niels Ramsing Holm, Aarhus University Hospital Skejby

Diagnostic Accuracy of On-line Quantitative Flow Ratio. Functional Assessment by Virtual Online Reconstruction (The FAVOR II Europe-Japan Study)

Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. QFR is assessed by calculation of the pressure in the vessel based on two angiographic projections. The purpose of the FAVOR II study is to evaluate the diagnostic accuracy of on-line QFR compared to 2D Quantitative Coronary Angiography (QCA) with FFR as gold standard.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Background:

Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by QCA, but fractional flow reserve is increasingly used to assess functional significance of identified stenosis. FFR is assessed during CAG by advancing a wire with a pressure transducer towards the stenosis and measure the ratio in pressure between the two sides of the stenosis during medical induced maximum blood flow (hyperaemia).

The solid evidence for FFR evaluation of coronary stenosis and the relative simplicity in performing the measurements have supported adoption of an FFR based strategy in many centers but the need for interrogating the stenosis by a pressure wire, the cost of the wire, and the drug inducing hyperaemia limits more widespread adoption.

Quantitative Flow Ratio is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.

The FAVOR I study (Tu et al.), showed promising results for core laboratory QFR analysis in selected patients.

The purpose of the FAVOR II study is to evaluate the feasibility and diagnostic precision of in-procedure QFR during CAG in comparison to QCA with FFR as gold standard for physiological lesion evaluation.

Hypothesis: QFR has superior sensitivity and specificity for detection of functional significant lesions in comparison to QCA with FFR as gold standard

Methods: Prospective, observational, multicenter study with inclusion of 310 patients.

Patients with indication for FFR are enrolled. At least two angiographic projections are acquired during resting conditions. QFR is calculated in-procedure using the Medis Suite application and simultaneously to the operator performing the FFR measurement. The QFR observer is blinded to the FFR measurement.

QFR is reassessed off-line by the Interventional Coronary Imaging Core Laboratory, Aarhus University, Denmark, blinded to FFR and in-procedure QFR results.

FFR is assessed by core laboratory reading, blinded to QFR results. All data are entered and stored in a protected and logged trial management system (TrialPartner, Aarhus University, Denmark).

Study Type

Observational

Enrollment (Actual)

329

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus N, Denmark, 8200
        • Aarhus University Hspital
      • Massy, France
        • Institut Cardiovasculaire Paris Sud Massy
      • Essen, Germany
        • Elizabeth Krankenhaus Essen
      • Giessen, Germany, 35392
        • Universitätsklinikum Gießen
      • Caserta, Italy
        • Azienda ospedaliera Sant'Anna e S. sebastiano di Caserta
      • Ferrara, Italy, 44124
        • Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara
      • Mestre, Italy, 30174
        • Ospedale Dell'Angelo Di Mestre
      • Gifu, Japan
        • Gifu Heart Center
      • The Hague, Netherlands, 2545
        • HagaZiekenhuis
      • Glasgow, United Kingdom, G81 4DY
        • Golden Jubilee National Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with stable angina pectoris admitted for coronary angiography due to high risk of significant coronary stenosis

Description

Inclusion Criteria:

  • Stable angina pectoris or secondary evaluation of stenosis after acute MI
  • Age > 18 years
  • Able to provide signed informed consent
  • Angiographic inclusion criteria:
  • Indication for FFR in at least one stenosis:
  • Diameter stenosis of 30%-90% by visual estimate
  • Reference vessel size > 2 mm in stenotic segment by visual estimate

Exclusion Criteria:

  • Myocardial infarction within 72 hours
  • Severe asthma or severe chronic obstructive pulmonary disease
  • Severe heart failure (NYHA≥III)
  • S-creatinine>150µmol/L or GFR<45 ml/kg/1.73m2
  • Allergy to contrast media or adenosine
  • Atrial fibrillation
  • Angiographic exclusion criteria:

Lesion specific

  • Below 30% and above 90% diameter stenosis by visual estimate.
  • Reference size of vessel below 2 mm by visual estimation.
  • Ostial LMCA lesions
  • Ostial RCA lesions
  • Distal LMCA lesions in combination with proximal Cx lesions
  • Other bifurcation stenosis with lesions on both sides of a major shift (>1mm) in reference diameter Angiographic quality
  • Poor image quality precluding contour detection
  • Good contrast filling not possible
  • Severe overlap of stenosed segments
  • Severe tortuosity of target vessel

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensitivity: Proportion of Patients With Positive QFR of FFR Positive Patients (True Positives) Compared to Proportion of Patients With Positive Percentual Diameter Stenosis (DS%) Assessed by 2D QCA of FFR Positive Patients (True Positives)
Time Frame: 1 hour
Positive FFR is defined as FFR≤0.80. Positive QFR is defined as QFR≤0.80. Positive DS% is defined as DS% > 50%
1 hour
Specificity: Proportion of Patients With Negative QFR of FFR Negative Patients (True Negatives) Compared to Proportion of Patients With Negative DS% Assessed by 2D QCA of FFR Negative Patients (True Negatives)
Time Frame: 1 hour
Negative FFR is defined as FFR>0.80. Negative QFR is defined as QFR>0.80. Negative DS% is defined as DS% ≤ 50%.
1 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Patients With Successful QFR in Patients With Successful FFR (Feasibility)
Time Frame: 1 hour
1 hour
Proportion of Patients With Positive QFR of FFR Positive Patients (True Positives) (Sensitivity)
Time Frame: 1 hour
Positive FFR is defined as FFR≤0.80. Positive QFR is defined as QFR≤0.80
1 hour
Proportion of Patients With Negative QFR of FFR Negative Patients (True Negatives) (Specificity)
Time Frame: 1 hour
Negative FFR is defined as FFR>0.80. Negative QFR is defined as QFR>0.80
1 hour
Proportion of Patients With Positive FFR (True Positives) of Patients With Positive QFR (Positive Predictive Value)
Time Frame: 1 hour
Positive FFR is defined as FFR≤0.80. Positive QFR is defined as QFR≤0.80
1 hour
Proportion of Patients With Negative FFR (True Negatives) of Patients With Negative QFR (Negative Predictive Value)
Time Frame: 1 hour
Negative FFR is defined as FFR>0.80. Negative QFR is defined as QFR>0.80
1 hour
Diagnostic Performance of QFR in Comparison to FFR Reported as Positive and Negative Likelihood Ratio
Time Frame: 1 hour
Positive likelihood ratio is defined as sensitivity/(1-specificity). Negative likelihood ratio is defined as (1-sensitivty)/specificity
1 hour
Diagnostic Grey Zone Calculation. QFR Limits for Achieving 95% Sensitivity and Specificity in Comparison to FFR
Time Frame: 1 hour

QFR limits to yield 95% sensitivity and specificity. The QFR limits are identified by Area under the receiver operating curve analysis.

QFR limits are defined as the numerical QFR ratios (0-1.00).

1 hour
Diagnostic Accuracy of TIMI-flow Based QFR in Comparison to 2D QCA (>50% Diameter Stenosis)
Time Frame: 1 hour

Comparison of proportion of participants correctly classified by QFR and 2D QCA using FFR as reference standard.

Diagnostic accuracy is defined as (true positives + false negatives) / (true positives+false positives+true negatives+false negatives).

Positive FFR is defined as FFR≤0.80. Positive QFR is defined as QFR≤0.80. Negative FFR is defines as FFR>0.80. Negative QFR is defines as QFR>0.80. Positive 2D QCA is defined as 2D-QCA % percent diameter stenosis >50. Negative 2D QCA is defined as 2D-QCA % diameter stenosis≤50.

1 hour
Participants With Myocardial Infarction (Number of Patients)
Time Frame: 1 day
Peri-procedural myocardial infarction
1 day
All-cause Mortality (Number of Patients)
Time Frame: 1 day
Peri-procedural mortality
1 day
Time to FFR
Time Frame: 1 hour
Time from starting preparations to do FFR (e.g. ordering assistants to prepare pressure wire, adenosine infusion etc.) to FFR value is obtained and drift has been verified to be within the prespecified limits
1 hour
Time to QFR After Receiving Angiographic Images
Time Frame: 1 hour
Time from first image evaluation on QFR computer until TIMI frame count based QFR value is obtained
1 hour
Contrast Use
Time Frame: 1 hour
Volume of contrast for total procedure
1 hour
Fluoroscopy Time
Time Frame: 1 hour
Fluoroscopy time for total procedure
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Niels R. Holm, M.D., Aarhus University Hospital, Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 22, 2017

Primary Completion (Actual)

October 17, 2017

Study Completion (Actual)

June 1, 2018

Study Registration Dates

First Submitted

November 7, 2016

First Submitted That Met QC Criteria

November 7, 2016

First Posted (Estimate)

November 9, 2016

Study Record Updates

Last Update Posted (Actual)

January 13, 2020

Last Update Submitted That Met QC Criteria

December 27, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on QFR (observational)

3
Subscribe